Page 62 - Read Online

Page 18 of 21 Persico et al. Rare Dis Orphan Drugs J 2023;2:xx https://dx.doi.org/10.20517/rdodj.2023.08

Medical visits at T0, T1, and T2: Persico AM, Cucinotta F
Psychological testing at T0, T1, and T2: Boncoddo M, Bellomo F, Turturo G
Response to medical requests from patients and families: Ricciardello A
Data curation: Ricciardello A, Turriziani L, Calabrese G, Tomaiuolo P, Di Bella T, Cucinotta F, Mirabelli S,
Persico AM
Statistical analysis: Banchelli F, Cuoghi Costantini R, Asta L, D’Amico R
Writing - original draft preparation: Cucinotta F, Ricciardello A, Turriziani L, Calabrese G, Tomaiuolo P, Di
Bella T
Writing - review and editing: Persico AM, Asta L
Read and agreed to the published version of the manuscript: Persico AP, Ricciardello A, Cucinotta F,
Turriziani L, Calabrese G, Tomaiuolo P, Di Bella T, Bellomo F, Boncoddo M, Turturo G, Mirabelli S, Asta
L, Banchelli F, Cuoghi Costantini R, D'Amico R

Availability of data and materials
All relevant data is contained within the article. The original contributions presented in the study are
included in the article; further inquiries can be directed to the corresponding author/s.

Financial support and sponsorship
This work was partly funded by the Italian Association for Phelan-McDermid Syndrome (AISPHEM).

Conflicts of interest
All authors declared that there are no conflicts of interest. The funders had no role in the design of the
study, in the collection, analyses, or interpretation of data, in the writing of the manuscript, or in the
decision to publish the results.

Ethical approval and consent to participate
The study was conducted in accordance with the ethical standards of the relevant national and institutional
committees on human experimentation and with the Helsinki Declaration. The study protocol was
approved by the Ethical Committee of the University of Messina (Messina, Italy) (prot. n. 15/18 approved
on 06/18/2018). Written informed consent was obtained from all caregivers for their own and their
children's participation.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2023.

REFERENCES
1. Phelan MC, Rogers RC, Saul RA, et al. 22q13 deletion syndrome. Am J Med Genet 2001;101:91-9. DOI
®
2. Phelan K, Rogers RC, Boccuto L. Phelan-McDermid syndrome. In M. P. Adam (Eds.) et. al., GeneReviews . University of
Washington, Seattle; 2005. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1198/ [Last accessed on 10 Jul 2023]
3. Phelan K, McDermid HE. The 22q13.3 deletion syndrome (Phelan-McDermid Syndrome). Mol Syndromol 2012;2:186-201. DOI
PubMed PMC
4. Kolevzon A, Angarita B, Bush L, et al. Phelan-McDermid syndrome: a review of the literature and practice parameters for medical
assessment and monitoring. J Neurodev Disord 2014;6:39. DOI PubMed PMC
5. National Organization for Rare Disorders. Phelan-cDermid sndrome. Available from: https://rarediseases.org/rare-diseases/phelan-
mcdermid-syndrome/#affected-populations [Last accessed on 7 Jul 2023].
6. Betancur C, Buxbaum JD. SHANK3 haploinsufficiency: a "common" but underdiagnosed highly penetrant monogenic cause of autism
spectrum disorders. Mol Autism 2013;4:17. DOI PubMed PMC